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It is known that a history of stroke or transient ischaemic 
attack (TIA) is a major risk factor for recurrent ischaemic 
events as well as bleeding in atrial fibrillation (AF), so effective 
anticoagulation is of key importance in this high-risk sub-
group. Therefore, I read with interest the paper by Lasek-Bal 
et al. [1]. The authors presented an observational study on 
Polish patients with AF and previous stroke or TIA, who were 
treated with rivaroxaban and followed-up for 24 months. The 
results support the use of rivaroxaban for prevention of re-
current stroke in patients with AF. There are still few studies 
confronting the current data obtained in Polish clinics with 
a rapidly growing number of international registries or those 
from Western European countries. A subgroup analysis of 
the ROCKET-AF study demonstrated that the efficacy and 
safety of rivaroxaban compared with warfarin did not differ 
among AF patients with or without previous stroke or TIA [2]. 
Unfortunately, the current study did not include a prospective 
or historic control group on vitamin K antagonists. It remains 
to established whether also in Poland rivaroxaban versus 
warfarin or acenocoumarol are similarly effective and safe 
when administered to real-life patients with nonvalvular AF. 
The authors focused on bleeding complications during 
follow-up and showed a rather low rate of these events (less 
than 1%, n = 2). Piccini et al. [3] reported in the ROCKET-AF 
study (with as many as 52% of AF patients following cerebro-
vascular events) that during a median follow-up of 1.9 years 
5.5% of patients experienced major bleeding. Surprisingly, 
epistaxis was common in this group (6.2%), while in the 
ROCKET-AF group 3.2% of the patients on rivaroxaban ex-
perienced this complication in contrast to about 50% of the 
bleeding patients who had upper or lower gastrointestinal tract 
bleeding (one case of a total of 25 in the present study) [3]. The 
odd pattern of the location of bleeds suggests that in a small 
cohort the incidence of bleeding events is barely predictable 
with the single benefit of paramount importance: intracranial 
bleedings are quite uncommon. For this reason, since none 
of the patients was lost to follow-up, it would also be of 
interest to show the characteristics of bleeding AF patients, 
their renal function in particular. Were there any differences 
in bleeding risk factors listed in the HAS-BLED scale or other 
independent risk factors for major bleeding already identified 
in the ROCKET-AF, namely a history of chronic obstructive 
pulmonary disease, increased age, baseline diastolic blood 
pressure ≥ 90 mm Hg, prior gastrointestinal bleeding, prior 
acetylsalicylic acid use, or anaemia [4]? Were all the 25 bleed-
ing patients in the high-risk group based on the HAS-BLED 
score, i.e. with three points or more? Moreover, given the slim 
chance of approving an antidote to factor Xa inhibitors (e.g. 
andexanet alpha currently tested in a phase III trial) in the 
near future, a practising Polish physician dealing with patients 
receiving rivaroxaban would appreciate information on the 
management of major bleedings in the patient group analysed 
by Lasek-Bal et al. [1]. Did the patients receive prothrombin 
complex concentrates, platelet concentrates, antifibrinolytics, 
or recombinant factor VIIa? Detailed information at least for 
the two patients who experienced major bleeding, including 
one case of intracranial bleed, could help optimise the man-
agement of rare bleeding events in patients on rivaroxaban 
in Polish hospitals.
To increase the safety of rivaroxaban use, laboratory 
monitoring of its anticoagulant effects could be considered. 
Poor adherence to this agent with a half-life of 8–12 h is 
a challenge and inter-individual differences in the anti-Xa 
activity at the similar time since the last intake of rivaroxaban 
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in subjects with normal renal function has been reported [5]. 
Moreover, anti-Xa activity is useful to confirm that a bleed-
ing patient has a detectable rivaroxaban concentration in 
the circulation, or when it is unclear when the patients with 
bleeding events have taken the last dose of the anticoagulant 
agent [6]. At least minor bleeding events on treatment do not 
correlate well with rivaroxaban concentrations [5]. A role of 
laboratory monitoring in a real-life setting of subjects taking 
rivaroxaban remains unclear.
It is advisable to run registries for treatment with rivaroxa-
ban in large clinical centres, to assess the impact of local fac-
tors known from everyday practice, for instance reduction of 
daily dose or its intake every other day, due to high cost of the 
treatment, which is not reimbursed in Poland. Increasing use 
of rivaroxaban, like other non-vitamin K oral anticoagulants in 
Poland, in which no specialised anticoagulation clinics were 
ever organised by our healthcare system in the whole country, 
is likely to lower the incidence of dangerous bleeding and 
thromboembolic complications of long-term anticoagulation 
in Polish patients with AF, and thus good long-term outcomes 
of everyday stroke prevention requires collection of data on 
anticoagulated patients in each outpatient clinic, including the 
benefits and adverse events of the therapy as presented by 
Lasek-Bal et al. [1]. Initiatives similar to that of Dr Lasek-Bal 
should be strongly encouraged.
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